Logo image of PLSE

PULSE BIOSCIENCES INC (PLSE) Stock Fundamental Analysis

NASDAQ:PLSE - Nasdaq - US74587B1017 - Common Stock - Currency: USD

17.07  +0.22 (+1.31%)

After market: 17.07 0 (0%)

Fundamental Rating

2

PLSE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. PLSE has a great financial health rating, but its profitability evaluates not so good. PLSE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PLSE had negative earnings in the past year.
In the past year PLSE has reported a negative cash flow from operations.
PLSE had negative earnings in each of the past 5 years.
PLSE had a negative operating cash flow in each of the past 5 years.
PLSE Yearly Net Income VS EBIT VS OCF VS FCFPLSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

PLSE has a worse Return On Assets (-40.45%) than 62.11% of its industry peers.
PLSE has a Return On Equity (-46.65%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -40.45%
ROE -46.65%
ROIC N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLSE Yearly ROA, ROE, ROICPLSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K 2.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PLSE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLSE Yearly Profit, Operating, Gross MarginsPLSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

8

2. Health

2.1 Basic Checks

PLSE has more shares outstanding than it did 1 year ago.
PLSE has more shares outstanding than it did 5 years ago.
PLSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLSE Yearly Shares OutstandingPLSE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLSE Yearly Total Debt VS Total AssetsPLSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

PLSE has an Altman-Z score of 34.66. This indicates that PLSE is financially healthy and has little risk of bankruptcy at the moment.
PLSE's Altman-Z score of 34.66 is amongst the best of the industry. PLSE outperforms 98.42% of its industry peers.
There is no outstanding debt for PLSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.66
ROIC/WACCN/A
WACCN/A
PLSE Yearly LT Debt VS Equity VS FCFPLSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 11.88 indicates that PLSE has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.88, PLSE belongs to the best of the industry, outperforming 95.26% of the companies in the same industry.
PLSE has a Quick Ratio of 11.88. This indicates that PLSE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.88, PLSE belongs to the best of the industry, outperforming 97.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.88
Quick Ratio 11.88
PLSE Yearly Current Assets VS Current LiabilitesPLSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

PLSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.68%, which is quite impressive.
Looking at the last year, PLSE shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)55.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLSE Yearly Revenue VS EstimatesPLSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 500K 1M
PLSE Yearly EPS VS EstimatesPLSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PLSE. In the last year negative earnings were reported.
Also next year PLSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLSE Price Earnings VS Forward Price EarningsPLSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLSE Per share dataPLSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PLSE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULSE BIOSCIENCES INC

NASDAQ:PLSE (5/9/2025, 8:16:14 PM)

After market: 17.07 0 (0%)

17.07

+0.22 (+1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11
Inst Owners9.9%
Inst Owner Change-5.68%
Ins Owners79.48%
Ins Owner Change10.23%
Market Cap1.15B
Analysts43.33
Price TargetN/A
Short Float %13.45%
Short Ratio12.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10
P/tB 10.36
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS1.71
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.45%
ROE -46.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.61%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.88
Quick Ratio 11.88
Altman-Z 34.66
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.68%
Cap/Depr(5y)25.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
EPS Next Y-17.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.99%
OCF growth 3YN/A
OCF growth 5YN/A